You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Citation Tools

Article menu

Download PDFPDF

Review
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Chae YK, Arya A, Iams W, et al
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Journal for ImmunoTherapy of Cancer 2018;6:39. doi: 10.1186/s40425-018-0349-3